Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin

BMJ Case Reports

Volumn 2016, Issue , 2016, Pages

  Rashid, Owais ^a   Farooq, Saad ^a   Kiran, Zareen ^a   Islam, Najmul ^b  

^a AGA KHAN UNIVERSITY   (Pakistan)

^b AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; INSULIN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ABDOMINAL PAIN; ADULT; ARTICLE; CASE REPORT; CONTINUOUS INFUSION; DIABETIC KETOACIDOSIS; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; VOMITING; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; PATHOPHYSIOLOGY;

ADULT; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; DRUG THERAPY, COMBINATION; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIRAGLUTIDE; MALE; METFORMIN; SODIUM-GLUCOSE TRANSPORTER 2; THIAZOLIDINEDIONES;

EID: 84969993109     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2016-215340     Document Type: Article

References (9)

1. Diabetic Ketoacidosis: practice essentials, background, pathophysiology [Internet]. Emedicine.medscape.com. 2016 [cited 6 March 2016]. http://emedicine.medscape. com/article/118361-overview
2. John M, Gopinath D, Jagesh R. Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: clinical perspectives. Indian J Endocrinol Metab 2016;20:22.
3. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes. Ann Intern Med 2013;159:262.
4. FDA. FDA Briefing Document. NDA 204042 Invokana (Canagliflozin) Tablets. 2013. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf (accessed 6 Mar 2016).
5. Storgaard H, Bagger JI, Knop FK, et al. Diabetic ketoacidosis in a patient with type 2 diabetes after initiation of sodium-glucose cotransporter 2 inhibitor treatment. Basic Clin Pharmacol Toxicol 2015;118:168-70.
6. Roach P, Skierczynski P. Euglycemic diabetic ketoacidosis in a patient with type 2 diabetes after treatment with empagliflozin. Diabetes Care 2015;39:e3.
7. EMA. Review of Diabetes Medicines Called SGLT2 Inhibitors Started: risk of diabetic ketoacidosis to be examined. 2016. http://www.ema.europa.eu/docs/en-GB/ document-library/Referrals-document/SGLT2-inhibitors-20/Procedure-started/ WC500187926.pdf (accessed 6 Mar 2016).
8. Cox K, Cocchi MN, Salciccioli JD, et al. Prevalence and significance of lactic acidosis in diabetic ketoacidosis. J Crit Care 2012;27:132-7.
9. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015;21:512-17.